Cancel
About Sal Rico
Sal Rico is the Chief Medical Officer with a strong background in pharmacology and clinical development, known for leading the development of gene therapies and contributing to the regulatory approval of various medical products.
Known information
Sal Rico serves as the Chief Medical Officer, holding a Doctor of Medicine and Surgery degree from the National Autonomous University of Mexico and further academic qualifications with an M.S. and a Ph.D. in pharmacology from the Universitat Autonoma de Barcelona. Previously, Rico was the senior vice president of clinical development at Audentes Therapeutics, where he led the clinical development of resamirigene bilparvovec, an adeno-associated virus (AAV)-based gene therapy for X-linked myotubular myopathy. His extensive experience includes participating in the design, conduct, and analysis of Phase I-IV clinical trials across multiple therapeutic areas. Additionally, Rico has played a significant role in the regulatory approval process of numerous drugs, biological products, and medical devices, enhancing his reputation in the medical and pharmaceutical fields.
About Encoded Therapeutics
Encoded Therapeutics focuses on developing precision gene therapies for pediatric central nervous system disorders, with its leading program, ETX101, targeting Dravet syndrome.
Report inaccurate information
